Your email has been successfully added to our mailing list.

×
0 0 0 -0.0285714285714285 -0.0571428571428571 -0.0571428571428571 -0.0637714285714285 -0.0742857142857142
Stock impact report

TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer

Tyme Technologies, Inc. (TYME) 
Last tyme technologies, inc. earnings: 2/5 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: tymeinc.com/investors
Company Research Source: GlobeNewswire
SM-88 therapy did not exhibit typical side effects associated with hormonal castration from androgen-deprivation therapy (ADT)87% of patients (20/23) remained free of radiographic progressionAfter 12 weeks, all patients had a decrease in circulating tumor cells (CTCs), a biomarker related to prostate cancer prognosis, with a median decrease of 65% Median Prostate-Specific Antigen (PSA) doubling time improved by 34%SM-88 presentations scheduled for Thursday, February 14 at the 2019 American Society of Clinical Oncology’s (ASCO) Genitourinary Cancers Symposium SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced encouraging preliminary results from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer. Co-authors from Albert Einstein College of Medicine, University of California, San Francisco and els Show less Read more
Impact Snapshot
Event Time:
TYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for TYME alerts
Opt-in for
TYME alerts

from News Quantified
Opt-in for
TYME alerts

from News Quantified